The discovery of the epidermal growth factor receptor (EGFR) and Kirsten Rat Sarcoma virus (KRAS) mutations in cf-DNA, for example, has fuelled interest in lung and colorectal cancer management techniques, which have been shown to be useful for tracking treatment response and prediction of relapse [59,60]. Here, EGFR is linked to colorectal cancer.